Moleculin reports positive Phase 1 results for WP1066 in pediatric malignant brain tumors

Moleculin Biotech, Inc.

WP1066 showed no significant toxicity and determined maximum feasible dose in 10 children with high-grade glioma.
Partial tumor response observed in a DIPG patient; anti-tumor immune responses demonstrated via STAT3 suppression.
Results published in Journal of Clinical Investigation Insight; Phase 2 trial warranted based on findings.
Compassionate use in 3 additional children with high-grade glioma also evaluated.
Study funded by Peach Bowl LegACy Fund and CURE Childhood Cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.